Pheniramine


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Allergic conditions; Prevention of motion sickness As maleate: Syr: 15-30 mg 2-3 times/day. Tab: Up to 45 mg 3 times/day. Max: 3 mg/kg/day. For motion sickness prevention: Take 1st dose at least 30 mins before travelling. Ophth Allergic conjunctivitis As 0.3% soln (w/ naphazoline HCl 0.025%): Max: 1-2 drops up to 4 times a day.
Dosage Details
Ophthalmic
Allergic conjunctivitis
Adult: Pheniramine maleate 0.3% in combination with naphazoline hydrochloride 0.025%: 1 or 2 drops in the affected eye/s up to 4 times a day.
Child: ≥6 yr: Pheniramine maleate 0.3% in combination with naphazoline hydrochloride 0.025%: 1 or 2 drops in the affected eye/s up to 4 times a day.

Oral
Prophylaxis of motion sickness
Adult: As maleate: Syrup: 15-30 mg bid or tid. Tablet: Up to 45 mg tid. Max: 3 mg/kg/day. Take 1st dose at least 30 min before travelling.
Child: As maleate: 5-10 yr: Half a 45-mg tablet up to tid; >10 yr: Syrup: 15-30 mg bid or tid. Tablet: Up to 45 mg tid. Max: 3 mg/kg/day. Take 1st dose at least 30 min before travelling.

Oral
Allergic conditions
Adult: As maleate: Syrup: 15-30 mg bid or tid. Tablet: Up to 45 mg tid. Max: 3 mg/kg/day.
Child: As maleate: 5-10 yr: Half a 45-mg tablet up to tid; >10 yr: Syrup: 15-30 mg bid or tid. Tablet: Up to 45 mg tid. Max: 3 mg/kg/day.
Elderly: As maleate: Syrup: 15-30 mg bid or tid. Tablet: Up to 45 mg tid. Max: 3 mg/kg/day.
Administration
Should be taken with food.
Contraindications
Symptomatic prostatic hypertrophy; neonates and premature infants.
Special Precautions
May impair ability to drive or operate machinery. Has potential for abuse. Narrow angle glaucoma, asthma or severe CV disease. Antiemetic effect may mask signs of other conditions. Pregnancy and lactation. Elderly.
Adverse Reactions
Oral: Sedation. Hypersensitivity reactions. Lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. Nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. Urinary retention. Palpitations, headache. Blurred vision, increased intraocular pressure. Muscular weakness. Rarely, blood dyscrasias e.g. agranulocytosis, haemolytic anaemia. Ophthalmic: Temporarily enlarged pupils, eye redness (overuse).
Overdosage
Symptoms: Agitation and convulsions (especially in children), and restlessness, disorientation and hallucinations in adults. Accidental ingestion in small children has resulted in convulsions and in some cases fatal. Treatment: No specific antidote; symptomatic and supportive. Gastric lavage may be useful for some time after ingestion. Do not use stimulants. Diazepam or short-acting barbiturates may be used to control convulsions. Vasopressors may be used for hypotension.
Drug Interactions
May mask ototoxicity produced by aminoglycoside antibiotics.
Potentially Fatal: Potentiation of CNS depression by alcohol, sedatives, opioids, barbiturates, hypnotics, narcoleptics. May increase antimuscarinic effect of MAOIs, atropine and TCAs.
Action
Description: Pheniramine is an alkylamine derivative with histamine H1-receptor antagonist effects. It also has anticholinergic and moderate sedative effects.
Onset: 15-20 min (oral).
Pharmacokinetics:
Absorption: Readily absorbed from the GI tract. Peak plasma concentrations in 1-2.5 hr.
Metabolism: Metabolised to N-desmethylpheniramine and N-didesmethylpheniramine.
Excretion: Via urine (as unchanged drug and metabolites). Terminal half-life: 8-17 hr (IV pheniramine maleate); 16-19 hr (oral).
Storage
Ophthalmic:
Store at 20-25°C (68-77°F). Protect from light.
Oral:
Tablet: Store below 30°C (86°F). Protect from light.
Disclaimer: This information is independently developed by MIMS based on Pheniramine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in